Dupilumab: what it is and how it is used in dermatology

Dupilumab, also known by the brand name Dupixent, is a laboratory-made monoclonal antibody. It attaches to part of the signalling pathway used by interleukin-4 and interleukin-13, two messengers involved in type 2 inflammation. By interrupting these signals, it can reduce the immune activity that contributes to certain inflammatory skin and allergic diseases.

It is given by injection under the skin on a schedule chosen for the condition, age, and treatment plan. It is not a steroid cream, antibiotic, or general immune suppressant. A clinician first checks whether the diagnosis and severity fit its approved use and whether other medicines or health conditions affect the plan.

Dupilumab is designed to act on a defined inflammatory pathway rather than broadly suppressing every part of the immune system. This focused action may lessen itching, redness, dryness, thickened patches, and flare activity when those features are driven by the pathway it targets. Improvement can be gradual, so the prescriber may continue moisturising and other topical care while judging the response.

Possible effects include injection-site irritation and eye symptoms such as dryness, redness, or conjunctivitis. New or worsening eye discomfort, vision change, or marked light sensitivity deserves prompt medical advice. The medicine can also affect the way some inflammatory conditions are monitored, so follow-up remains part of safe treatment.

In dermatology, dupilumab is used for suitable people with moderate-to-severe atopic dermatitis when topical treatment is not enough, not suitable, or has not controlled the condition. It may also be used in other type 2 inflammatory diseases under the relevant specialist, including some asthma and chronic rhinosinusitis with nasal polyps plans. The exact indication depends on local approval and the person's clinical picture.

A skin examination helps distinguish atopic dermatitis from infection, contact dermatitis, psoriasis, or another cause of a rash. Dupilumab does not replace treatment for a bacterial, viral, or fungal infection, and it is not a cosmetic skin-brightening injection.

Alternatives depend on the diagnosis and how extensive or persistent the inflammation is. They can include regular emollients, topical corticosteroids, topical calcineurin inhibitors, short courses of other prescribed anti-inflammatory treatments, phototherapy, or another systemic medicine. Each option has a different balance of application burden, monitoring, speed of effect, and suitability for pregnancy, age, or other health conditions.

Do not stop a prescribed medicine or switch to an injectable treatment without a review. A dermatologist can compare the options with your flare pattern, infection history, eye symptoms, previous treatments, and ability to attend follow-up.

Before starting, tell the clinician about eye disease, recurring cold sores, parasite infections, vaccinations, pregnancy or breastfeeding, and every medicine or supplement you use. Learn the injection technique, storage instructions, missed-dose plan, and the symptoms that should trigger contact with the care team. Continue gentle cleansing, moisturising, and avoidance of known irritants unless your clinician gives different advice.

Seek urgent help for breathing difficulty, facial or throat swelling, faintness, or a rapidly spreading severe reaction after a dose. Contact the treating team promptly for significant eye pain, vision changes, persistent fever, or a rash that looks infected. A treatment review is useful if flares remain frequent or the medicine is difficult to tolerate.

Dupilumab is generally considered a continuing treatment rather than a one-time cure. The clinician reviews skin control, unwanted effects, adherence, and the ongoing need for treatment at follow-up visits. If it is stopped, the underlying inflammatory condition may become active again; the next step should be planned rather than decided from a single difficult day.

Keep the medicine in its original storage conditions and never use a dose that has been handled or stored outside the instructions. Ask before receiving a live vaccine, and report new symptoms rather than concealing them. The full treatment plan, including topical care, matters even when the injection is helping.